Th22细胞及其效应因子在自身免疫性皮肤病中的作用研究进展

摘要
图/表
参考文献(33)
相关文章 (4)

全文: PDF (0 KB) HTML (45 KB)
输出: BibTeX | EndNote (RIS)

摘要 Th22细胞是近年来最新发现的CD4+T细胞亚群，可通过分泌白介素-22（IL-22）、肿瘤坏死因子（TNF-α）及少量的白介素-13（IL-13）和白介素-26（IL-26）等细胞因子而发挥作用，并且能特征性地表达趋化因子受体（CCR）CCR6+、CCR4+和CCR10+，与皮肤的病理生理及稳态之间存在着密切联系。近年来部分研究发现Th22细胞在某些皮肤病中尤其是自身免疫性皮肤病及其不同发展时期表达程度明显不同。由此提示Th22细胞可能与疾病的活动度密切相关，提示在免疫性皮肤病中可能发挥至关重要的作用。本研究就近年来Th22细胞在自身免疫性皮肤病中的表达程度相关研究进展作一综述，为其在此类皮肤病中的作用提供理论依据，同时也为明确相关疾病的发病机制及有效治疗方案提供新的思路和见解。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	徐欣欣
	孙其乐
	王一汀
	王忠永

关键词 ： Th22, 系统性硬化症, 红斑狼疮, 贝赫切特综合征

Abstract：Th22 cells are the newly discovery of CD4+T cell subsets in recent years.They can secrete interleukin-22(IL-22),tumor necrosis factor(TNF-α)and a small amount of interleukin-13(IL-13)and interleukin-26(IL-20)and can express CCR6+,CCR4+and CCR10+in CC chemokine receptor(CCR),which are closely to the pathophysiology and homeostasis of the skin.In recent years,some studies have found that the expression level of Th22 cells in some skin diseases,especially in autoimmune dermatal diseases and their different development stages are significantly different,which suggests that Th22 cells may be closely related to the degree of disease activity,indicating that they may play a crucial role in immune dermatosis.The research reviews recent advances in the level of expression of Th22 cells in autoimmune dermatoses,so as to provide a theoretical basis for their role in this type of dermatology and also provide new ideas and insights for clear understanding of the pathogenesis and effective treatment of related diseases.

Key words： Th22 Systemic sclerosis Systemic lupus erythematosus Behcet&prime s disease

作者简介: 徐欣欣（1992-），女，山东德州人，滨州医学院2016年在读硕士研究生，皮肤病与性病学专业，研究方向：免疫性皮肤病的发生机制

引用本文:

徐欣欣;孙其乐;王一汀;王忠永. Th22细胞及其效应因子在自身免疫性皮肤病中的作用研究进展[J]. 中国当代医药, 2018, 25(25): 43-46.
XU Xin-xin;SUN Qi-le;WANG Yi-ting;WANG Zhong-yong. Research advance of Th22 cell and its effectors in the role of autoimmunol dermatal diseases. 中国当代医药, 2018, 25(25): 43-46.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2018/V25/I25/43

[1]	Duhen T，Geiger R，Jarrossay D，et al.Production ofinterleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells[J].Nat lmmunol，2009，10（8）：857-863.
[2]	Tfifari S，Kaplan CD，Tran EH，et al.Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17，TH-1 and TH-2 cells[J].Nat Immunol，2009，10（8）：864-871.
[3]	Ouyang WJ，KoIIs JK，Zheng Y.The biological functions of T helper 17 cell effector cytokines in infIammation[J].Immunity，2008，28（4）：454-467.
[4]	Eyerich S，Wagener J，WenzeI V，et al.IL-22 and TNF-a represent a key cytokine combination for epidermal integrity during infection with Candida albicans[J].Eur J Immunol，2011，41（7）：1894-1901.
[5]	Kerstin W，Ellen W，Katrin W，et al.Biology of interleukin-22[J].Semin Immunopathol，2010，32（1）：17-31.
[6]	Schulze-Tanzil G，Zreiqat H，Sabat R，et al.Interleukin-10 and articular cartilage：experimental therapeutical approachesin cartilage disorders[J].Curr Gene Ther，2009，9（4）：306-315.
[7]	Lisa AM，Sarah AJ，Mathilde R，et al.Retinoic acid expression associates with enhanced IL-22 production by γδT cells and innate lymphoid cells and attenuation of intestinal inflammation[J].J Exp Med，2013，210（6）：1117-1124.
[10]	Dudakov JA，Hanash AM，van den Brink MR.Interleukin-22：immunobiology and pathology[J].Annu Rev Immunol，2015，33：747-785.
[11]	Muhl H，Scheiermann P，Bachmann M，et al.IL-22 in tissue-protective therapy[J].Pharmacol，2013，169（4）：761-771.
[12]	Eidenschenk C，Rutz S，Liesenfeld O，et al.Role of IL-22 in microbial host defense[J].Curr Top Microbiol Immunol，2014，380：213-236.
[8]	Zindl CL，Lai JF，Lee YK，et al.IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis[J].Proc Natl Acad Sci USA，2013，110（31）：12768-12773.
[9]	Perusina LM，Lin Y，Fang J，et al.Biological and pathological activities of interleukin-22[J].J Mol Med（Berl），2016，94（5）：523-534.
[13]	Li LJ，Gong C，Zhao MH，et al.Role of interleukin-22 in inflammatory bowel disease[J].World J Gastroenterol，2014，20（48）：18177-18188.
[14]	EyerichK，Dimartino V，Cavani A.IL-17 and IL-22 in immunity：Driving protection and pathology[J].Eur J Immunol，2017，47（4）：607-614.
[15]	Mathian A，Parizot C，Dorgham K，et al.Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions[J].Ann Rheum Dis，2012，71（7）：1227-1234.
[16]	Aden N，Nuttall A，Shiwen X，et al.Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis[J].Invest Dermatol，2010，130（9）：2191-2200.
[17]	Brembilla NC，Dufour AM，Alvarez M，et al.IL-22 capacitates dermal fibroblast responses to TNF in scleroderma[J].Ann Rheum Dis，2016，75（9）：1697-1705.
[18]	Mathian A，Parizot C，Dorgham K，et al.Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions[J].Ann Rheum Dis，2012，71（7）：1227-1234.
[19]	Liu M，Wu W，Sun X，et al.New insights into CD4+T cell abnormalities in systemic sclerosis[J].Cytokine Growth Factor Rev，2016，28：31-36.
[20]	Brembilla NC，Dufour M，Alvarez M，et al.IL-22 capacitates dermal fibroblast responses to TNF in scleroderma[J].Ann Rheum Dis，2015，75（9）：1697-1705.
[21]	Wolk K，Haugen HS，Xu W，et al.IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not[J].J Mol Med （Berl），2009，87（5）：523-536.
[22]	Moulton VR，Tsokos GC.T cell signaling abnormalities contribute toaberrant immune cell function and autoimmunity[J].J Clin Invest，2015，125（6）：2220-2227.
[23]	Bernatsky S，Smargiassi A，Barnabe C，et al.Fine particulate air pollutionand systemic autoimmune rheumatic disease in two Canadian provinces[J].Environ Res，2016，146，85-91.
[24]	Zhu X，Xu J，Li S，et al.Role of abnormal anterior pituitary hormones-growth hormone and prolactin in active systemic lupus erythematosus[J].J Clin Exp Med，2015，8（10）：19223-19231.
[25]	Chauhan，Moore，Chen，et al.Fc（RⅢa-Syk co-signal）modulates CD4+T cell response and up-regulates toll-like receptor（TLR）expression[J].J Biol Chem，2016，291（3）：1368-1386.
[26]	Jafari-Nakhjavani，Abedi-Azar，Nejati，et al.Correlation of plasma interleukin-18 concentration and severity of renal involvement and disease activity in systemic lupus erythematosus[J].J Nephropathol，2016，5（1）：28-33.
[27]	Yang XY，Wang HY，Zhao XY，et al.Th22，but not Th17 might be a good index to predict the tissue involvement of systemic lupus erythematosus[J].Immunology，2013，33（4）：767-774.
[28]	Zhao L，Jiang Z，Jiang Y，et al.IL-22+CD4+T-cells in patients with active systemic lupus erythematosus[J].Exp Biol Med，2013，238（2）：193-199.
[29]	Zhao L，Ma H，Jiang Z，et al.Immunoregulation therapy changes the frequency of interleukin （IL）-22+CD4+T cells in systemic lupus erythematosus patients[J].Clin Exp Immunol，2014，177（1）：212-218.
[30]	Lin J，Yue LH，Chen WQ.Decreased plasma IL-22 levels and correlations with IL-22-producing T helper cells in patients with new-onset systemic lupus erythematosus[J].Immunology，2014，79（2）：131-136.
[31]	Zhong W，Jiang Y，Ma H，et al.Elevated levels of CCR6+T helper 22 cells correlate with skin and renal impairment in systemic lupus erythematosus[J].Sci Rep，2017，7（1）：12962.
[32]	Esin AC，Fulya C，Ayse C，et al.IL-22-secreting Th22 and IFN-γ-secreting Th17 cells in Behcet′s disease[J].Mod Rheumatol，2014，24（5）：802-807.
[33]	Sugita S，Kawazoe Y，Imai A，et al.Role of IL-22-and TNF-α-producing Th22 cells in uveitis patients with Behcet's disease[J].Immunology，2013，190（11）：5799-5808.